Patents by Inventor Loraine V. Upham

Loraine V. Upham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME
    Publication number: 20150056167
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Application
    Filed: September 4, 2014
    Publication date: February 26, 2015
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • COMPOSITIONS AND METHODS OF USING PROISLET PEPTIDES AND ANALOGS THEREOF
    Publication number: 20150018272
    Abstract: Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof.
    Type: Application
    Filed: August 22, 2014
    Publication date: January 15, 2015
    Inventors: Claresa S. Levetan, Victor M. Garsky, Loraine V. Upham
  • Methods And Compositions Relating To Islet Cell Neogenesis
    Publication number: 20150010508
    Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Peptides, derivatives and analogs thereof, and methods of using same
    Patent number: 8829158
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: September 9, 2014
    Assignee: CureDM Group Holdings, LLC
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Compositions and methods of using proislet peptides and analogs thereof
    Patent number: 8816047
    Abstract: Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: August 26, 2014
    Assignee: Cure DM Group Holdings, LLC
    Inventors: Claresa S. Levetan, Victor M. Garsky, Loraine V. Upham
  • Methods and compositions relating to islet cell neogenesis
    Patent number: 8785400
    Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: July 22, 2014
    Assignee: CureDM Group Holdings, LLC
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Peptides, derivatives and analogs thereof, and methods of using same
    Patent number: 8383578
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: February 26, 2013
    Assignee: CureDM Group Holdings, LLC
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
    Patent number: 8211430
    Abstract: Methods for treating type 1 diabetes mellitus or a condition resulting from the loss of pancreatic islet cells in a patient are disclosed herewith. The method of treatment comprises co-administration of human proislet peptides (HIP); and an agent that inhibits the activity of autoimmune cells.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: July 3, 2012
    Assignee: Curedm Group Holdings, LLC
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME
    Publication number: 20110280833
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Application
    Filed: June 24, 2011
    Publication date: November 17, 2011
    Applicant: CUREDM GROUP HOLDINGS, LLC
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Peptides, derivatives and analogs thereof, and methods of using same
    Patent number: 7989415
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: August 2, 2011
    Assignee: CureDM Group Holdings, LLC
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Peptides, derivatives and analogs thereof, and methods of using same
    Patent number: 7714103
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: May 11, 2010
    Assignee: CureDM, Inc.
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME
    Publication number: 20100093605
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Application
    Filed: December 10, 2009
    Publication date: April 15, 2010
    Applicant: CUREDM, INC.
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Methods and Compositions Relating to Islet Cell Neogenesis
    Publication number: 20090068145
    Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.
    Type: Application
    Filed: November 21, 2007
    Publication date: March 12, 2009
    Applicant: CureDM, Inc.
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME
    Publication number: 20080300190
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Application
    Filed: May 15, 2008
    Publication date: December 4, 2008
    Applicant: CureDM, Inc.
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Peptides, derivatives and analogs thereof, and methods of using same
    Patent number: 7393919
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: July 1, 2008
    Assignee: Cure DM, Inc.
    Inventors: Claresa S. Levetan, Loraine V. Upham